Evidence map›Paper›PMID 34213662›Full record

ArticleJournal of cancer research and clinical oncology2021

A metal-free salalen ligand with anti-tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway.

Sina M Pütz, Qifang Wang, Corazon Frias, Marie Ahrweiler, Nicola Wilke, Nathalie Wilke, Albrecht Berkessel, Aram Prokop

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sina M PützDepartment of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children's Hospital of the City Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany. sina.hopff@uk-koeln.de.ORCID 0000-0002-8886-4596
Qifang WangDepartment of Chemistry, University of Cologne, Greinstraße 4, 50939, Cologne, Germany.
Corazon FriasDepartment of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children's Hospital of the City Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
Marie AhrweilerDepartment of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children's Hospital of the City Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
Nicola WilkeDepartment of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children's Hospital of the City Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
Nathalie WilkeDepartment of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children's Hospital of the City Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
Albrecht BerkesselDepartment of Chemistry, University of Cologne, Greinstraße 4, 50939, Cologne, Germany.
Aram ProkopDepartment of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children's Hospital of the City Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
University Hospital Cologne · DEUniversity of Cologne · DEMSH Medical School Hamburg – University of Applied Sciences and Medical University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSince the discovery of the well-known cis-platin, transition metal complexes are highly recognized as cytostatic agents. However, toxic side effects of the metal ions present in the complexes may pose significant problems for their future development. Therefore, we investigated the metal-free salalen ligand WQF 044.

methodsDNA fragmentations in leukemia (Nalm6) and solid tumor cells (BJAB, MelHO, MCF-7, RM82) proved the apoptotic effects of WQF 044, its overcoming of resistances and the cellular pathways that are affected by the substance. The apoptotic mechanisms finding were supported by western blot analysis, measurement of the mitochondrial membrane potential and polymerase chain reactions.

resultsA complex intervention in the mitochondrial pathway of apoptosis with a Bcl-2 and caspase dependence was observed. Additionally, a wide range of tumors were affected by the ligand in a low micromolar range in-vitro. The compound overcame multidrug resistances in P-gp over-expressed acute lymphoblastic leukemia and CD95-downregulated Ewing's sarcoma cells. Quite remarkable synergistic effects with vincristine were observed in Burkitt-like lymphoma cells.

conclusionThe investigation of a metal-free salalen ligand as a potential anti-cancer drug revealed in promising results for a future clinical use.

Indexed as

Drug SynergismAntineoplastic AgentsApoptosisCell ProliferationCisplatinDrug Resistance, MultipleDrug Resistance, NeoplasmHumansLeukemiaLigandsMitochondriaNeoplasmsTumor Cells, CulturedAntineoplastic AgentsCisplatinLigandsApoptosisMetal-free ligandMitochondrial pathwayMultidrug resistanceSalalenSynergistic effects

Identifiers

PMID34213662
PMCPMC8310854
OpenAlexW3175268062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.